Compare Citius Pharmaceuticals Inc (CTXR) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs KeyCorp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while KeyCorp trades at $19.98 (market cap $21.45B). The key difference: KeyCorp is far larger — about 1574.9× Citius Pharmaceuticals Inc's market cap, and KeyCorp pays a 4.08% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and KeyCorp for 66 Days on average.
| CTXR | KEY | |
|---|---|---|
Market Cap | $13.62M | $21.45B |
Volume | 132,438 | 19,450,846 |
Sector | Health | Financials |
52-Week High | $1.82 | $23.99 |
52-Week Low | $0.48 | $16.78 |
Typical Hold Time | 17 Days | 66 Days |
Enterprise Value | $3.79M | $34.63B |
Dividend Yield | — | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
KeyCorp (KEY) trades at $19.985, up 0.78% on the day, with strong fundamental metrics including a P/E of 11.75 and net income margin of 26.72%. The stock shows consistent earnings beats in recent quarters and maintains a solid dividend yield. Technical indicators suggest bearish momentum despite neutral oscillators, while analyst consensus remains strongly bullish with a $25.00 price target representing 25% upside potential from current levels.
KEY presents a compelling value opportunity with attractive valuation multiples and strong profitability, though technical weakness and frozen dividend payments pose near-term concerns. The bank's improved revenue guidance for 2026 and aggressive share buyback program support EPS growth, while interest rate sensitivity remains a key risk factor for the regional banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
